Nonnecrotizing Granulomatous Lymphadenitis mimicking Hodgkin Lymphoma relapse by $^{18}$F-FDG PET/CT after stem cell transplantation. Report of a case

Luis G Díaz$^{1,2,*}$, Jorge Labrador$^3$, Carlos A Achury$^1$, Norma C Gutiérrez$^{2,4}$, Gerardo J Hermida$^1$ and Pilar Tamayo$^{1,2}$

$^1$Nuclear Medicine Department, University Hospital of Salamanca, Spain
$^2$IBSAL (Salamanca Institute of Biomedical Research), Salamanca, Spain
$^3$Hematology Department, University Hospital of Burgos, Spain
$^4$Hematology Department, University Hospital of Salamanca, Spain

Abstract

$^{18}$F-FDG PET-CT has become the main procedure for staging and monitoring treatment response in patients with lymphoma. It can differentiate between active disease and necrosis/fibrosis in after treatment residual masses, mainly in Hodgkin Lymphoma patients. Persistence of FDG uptake is very suggestive of resistance or recurrence. However, there can be also some false positives (FP). Non necrotizing Granulomatous Lymphadenitis (NNGL) is a sarcoidosis-like inflammatory reaction and it can be a FP cause in PET-CT monitorization of HL treatment response. Here we present a case of a patient with HL who was NNGL PET positive after stem cell transplantation.

Introduction

$^{18}$F-FDG PET/CT has replaced conventional imaging techniques and become the main procedure for staging and monitoring treatment response in patients with lymphoma, emphasizing Hodgkin Lymphoma (HL) and Diffuse Large B Cell Lymphoma (DLBCL) [1,2]. PET-CT can differentiate between metabolically active disease and necrosis/fibrosis in after treatment residual masses, mainly in HL patients, which can reach a very high Negative Predictive Value (95-100%) and Positive Predictive Value of more than 90% [1,3-6]. Persistence of lymph nodes with FDG uptake after treatment is very suggestive of resistance or recurrence.

However, there can be also some false positives (FP), so starting a second line treatment without taking a previous biopsy could develop in unnecessary and potentially toxic therapies, as aggressive chemotherapy or even a stem cell transplantation (SCT). The most frequent causes of FP are infections and inflammatory-granulomatous diseases [7-10]. Non necrotizing Granulomatous Lymphadenitis (NNGL) is a sarcoidosis-like inflammatory reaction, mainly associated with lymphomas and carcinomas. Although infrequent, however, it can be a FP cause in PET-CT monitoring of HL treatment response [10]. Here we present a case of a patient with HL who was NNGL PET positive after SCT.

Case Report

Female (aged 27 years), diagnosed with nodular lymphocyte-predominant HL in 1997, Ann Arbor stage II-A, who reached complete response after treatment with 3 cycles of ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) scheme followed by radiotherapy. In October 2015, aged 44 years, nodular lymphocyte-predominant HL recurrence was diagnosed, also staged II-A (bilateral axillary nodal disease). She received rescue chemo with two courses of R-ESHAP regimen [11], achieving a second complete remission, and after that, she underwent an autologous SCT in 2-2-2016.

In day + 100 after SCT, a $^{18}$F-FDG PET/CT was performed. It showed focal uptake in lymph nodes (located in the mediastinum, pulmonary and liver hilum and retroperitoneum) and several locations in bone (Figures 1 and 2). Despite this result, the patient was clinically asymptomatic and blood parameters (VSG, LDH, Beta 2 microglobulin) were all normal.

Because of this clinical incongruence, a mediastinoscopy was performed. The final diagnosis was nonnecrotizing granulomatous lymphadenitis, so monitoring was decided. Finally, a new PET-CT performed 9 months after showed no metabolically active disease (Figures 1 and 2).

Discussion

$^{18}$F-FDG PET/CT is standard method for staging and monitoring of treatment response in lymphomas, because of its high sensibility (>95%). However, its specificity is lower [1,2]. The most frequent causes of FP in lymphoma patients are other malignant diseases,

*Correspondence to: Luis G Diaz, Nuclear Medicine Department, University Hospital of Salamanca, Spain, Tel: +34635038969; E-mail: lgdiaz@saludcastillayleon.es

Key words: $^{18}$F-FDG; PET-CT, hodgkin lymphoma, false positive, non-necrotizing granulomatous lymphadenitis, stem cell transplantation

Received: March 05, 2019; Accepted: March 18, 2019; Published: March 21, 2019
In conclusion, PET-CT is the best method for monitoring therapy response in patients with HL. However, new hypermetabolic foci in the after treatment PET-CT are not always due to lymphoma. Our case shows that confirmation biopsy is mandatory in those patients whose recurrence or residual disease is clinically unprobeable, to avoid incorrect and potentially toxic therapies.

Disclosure

The authors state no conflict of interests.

References

1. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, et al. (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32: 3059-3068.

2. Barrington SF, Mikhail NG, Kostakoglu L, Meigman M, Hutchings M, et al. (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Nucl Oncol 32: 3048-3058.

3. Cerchi JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, et al. (2010) 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 51: 1337-1343. [Crossref]

4. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, et al. (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379: 1791-1799.

5. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, et al. (2001) 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 12: 29-37. [Crossref]

6. Dittmann H, Sokler M, Kollmannsberger C, Dohmen BM, Baumann C, et al. (2001) Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 8: 1393-1399. [Crossref]

7. Paydas S, Yavuz S, Disel U, Zeren H, Hastürk S, et al. (2002) Granulomatous reaction of Hodgkin's lymphoma. A favorable prognostic sign? J Clin Oncol 91: 233: 886-889. [Crossref]

8. Fallanca F, Picchio M, Crivellaro C, Mapelli P, Samanes Gajate AM, et al. (2012) Unusual presentation of sarcoid-like reaction on bone marrow level associated with recurrent Hodgkin's lymphoma. Rev Esp Med Nucl Imagen Mol 31: 207-209.

9. Wirk B (2010) Sarcoid Reactions after Chemotherapy for Hodgkin's Lymphoma. Clin Med Insights Case Rep 3: 21-25. [Crossref]

10. Cherk MH, Pham A, Haydon A (2011) 18F-fluorodeoxyglucose positron emission tomography-positive sarcoidosis after chemoradiotherapy for Hodgkin's disease: a case report. J Med Case Rep 5: 247.

11. Labrador J, Cabrero-Calvo M, Pérez-López E, Mateos MV, Vázquez L, et al. (2014) ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. Ann Hematol 93: 1745-1753. [Crossref]

12. Sanan P, Lu Y (2017) Multiorgan involvement of chemotherapy-induced sarcoidosis mimicking progression of lymphoma on FDG PET/CT. Clin Nucl Med 42: 702-703.

13. Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, et al. (1998) Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91: 3340-3346. [Crossref]